

| TRIALTROVE⁺
| SITETROVE⁺

CITELINE
CLINICAL

Use Case

Expediting Clinical Trial Planning and Site Selection with Trialtrove⁺ and Sitetrove⁺





Challenge

A mid-size biopharma company is preparing for a Phase III clinical trial in a competitive therapeutic area. The study team is facing challenges in:



Identifying the most suitable trial sites and investigators with strong performance records

“We are trying to branch out from always using the same sites.”

HEAD OF PATIENT RECRUITMENT AND FEASIBILITY AT MID-SIZE PHARMA




Benchmarking site start-up times and performance metrics to optimize feasibility planning



Reducing screen failure rates and improving patient retention



Streamlining data analysis and decision-making for study start-up





Solution: Trialtrove+ and Sitetrove+

By leveraging the next-generation capabilities of Trialtrove+ and Sitetrove+, the study team can address these challenges effectively.

1 Optimized KOL Identification with Expert Finder

Using **Expert Finder**, the team identifies KOLs with a proven track record in their therapeutic area. With data on over 580,000 investigators, including claims, journals, publications, payments, NIH grants, congress participation, and social media presence, the team shortlists experts who align with their study criteria and can support their study.


The screenshot displays the 'Expert Finder' interface within the CITELINE CLINICAL system. At the top, a summary bar shows key metrics: Total Trials (462,540), Total Claims (4,534,779,085), Total Journals (18,566), Total Publications (11,090,038), Total Payments (\$55.7B), and Total NIH Grants (\$771B). Below this, the interface is divided into 'EXPERTS (586,625)' and 'SELECTED EXPERTS (54/100)'. A table lists individual experts with columns for Expert Name, Primary Organization Name, Trials, Claims, Journals, Publications, Payments, and NIH Grants. Several experts are marked as selected with blue checkmarks.

Expert Name	Primary Organization Name	Trials	Claims	Journals	Publications	Payments	NIH Grants
<input type="checkbox"/> Shaker Dakhil	Cancer Center of Kansas, P.A. - Wichita - Heritage Plaza Medical Building	793	98,261	58	177	\$14.4M	\$31.7M
<input type="checkbox"/> Ying Cheng	Jilin Cancer Hospital	754	0	0	0	\$0	\$0
<input checked="" type="checkbox"/> Howard Gross	Dayton Physicians Network - Hematology and Medical Oncology - Miami Valley Hospital North Location	577	97,281	18	27	\$442K	\$22M
<input checked="" type="checkbox"/> James Wade	Cancer Care Specialists of Illinois (CCSI) - Cancer Care Center of Decatur	577	18,892	48	117	\$3.34M	\$24.1M
<input checked="" type="checkbox"/> James Atkins	Atrium Health Wake Forest Baptist - Wilkes Medical Center	530	24,006	64	144	\$482K	\$25.8M
<input type="checkbox"/> Philip Stella	Physician Resource Management, Inc. (PRM)	529	21,525	35	79	\$3.82M	\$28.4M
<input type="checkbox"/> Hagoop Kantarjian	The University of Texas-MD Anderson Cancer Center - Leukemia Center	525	8,475	191	2,316	\$108M	\$19.9M
<input type="checkbox"/> John Ellerton	OptumCare Cancer Care (Nevada Cancer Specialists) - Fort Apache	498	137,383	10	17	\$1.95M	\$19.1M
<input type="checkbox"/> Alan Kivitz	Altoona Arthritis & Osteoporosis Center (AAOC) - Altoona Center for Clinical Research (ACCR)	486	81,284	52	164	\$33.8M	\$0
<input type="checkbox"/> Lin Shen	Peking University Cancer Hospital (Beijing Cancer Hospital) (Beijing Institute for Cancer Research)	464	0	0	0	\$0	\$0



2 Data-driven Feasibility and Start-up Planning with Performance Metrics

Through various **Performance Metrics**, the team gains visibility into key site performance indicators, including start-up cycle times, dropout rates, and screen failure rates. By layering in proprietary derived aggregated data points, they can confidently select sites and countries with historically shorter start-up times and higher patient retention rates, leading to a more efficient trial launch.





Additionally, **the Site Compare Tool** allows the team to compare site capacity, experience, and trial performance among different sites, helping them make more informed decisions.



3

Deeper Insights through Interactive Visualizations with Analytics

The **Analytics** dashboard enables the team to assess global trial trends, evaluate competitive landscapes, and identify potential roadblocks. Instead of manually extracting and manipulating data in external tools, the team now has access to interactive charts, tables, and predictive insights directly within the platform. **Clinical Trial Trends** and **Trial Activity Landscape Analysis** allow the team to visualize historical trial data by disease, sponsor, drugs, patient segment, and country, optimizing trial planning.







4

AI-powered Insights with Ella

With **Ella, the AI chat assistant**, the team accelerates research by quickly retrieving relevant trial and site data, applying automated filters, and receiving answers in real time. **Ella can create searches and validate search strategies**, saving the team significant time that would otherwise be spent manually reviewing data.





5

Enrollment Performance Benchmarking

The **Trial Health Calculator** helps benchmark trial recruitment performance against industry expectations, allowing the team to better assess if enrollment issues are trial-specific or part of broader industry trends.

CITELINE CLINICAL

Advanced Analytics > Trial Health Calculator

Run a Trial Health Calculator

Input your trial NCTID or protocol ID to assess trial competition and whether your existing sites are recruiting on pace.

NCT04995523

Run Trialhealth Analysis

All data is sourced via Citeline Trialtrove and Sitetrove.

Review Your Trialhealth analysis below for: **NCT04995523**
 Results are based on available data in Trialtrove and Sitetrove. Learn how result are calculated [here](#)

TrialHealth Calculator
 Calculate the recruitment rate needed to hit your LPI target.
 Enter the number of patients you've enrolled to date to accurately calculate a trial's current recruitment rate in the graph below. Note that if the Last Patient In (LPI) field is blank, you will need to manually enter that date as well for an accurate calculation.

No study health check query is stored by Citeline.

Total Number of Reported Sites * 48 Target Accrual * 199 Number of Patients Enrolled to Date * 130 First Patient In Date * 14/Sep/2021 Last Patient In Date * 11/Dec/2025

21.84 Months
 Left until the completion of enrollment
Fields marked with an * are required.

Additionally, **Enrollment Performance Metrics** provide the team with insights into patients per site per month, enrollment rates, and screen failure metrics by country, therapeutic area, disease, and patient segment.

CITELINE CLINICAL

Navigation <

Overview
Trends
Landscape
Study Activity
Enrollment
Trial Health Calculator

Views Selection
Country

Patient per Site per Month by Country

Oncology Lung, Non-Small Cell

Country	Enrollment Rate (approx.)
South Africa	1.35
Pakistan	1.25
Georgia	1.15
Bosnia and Herzegovina	1.05
Egypt	0.95
Japan	0.85
Iceland	0.80
Belarus	0.75
Nigeria	0.70
China	0.65
India	0.60
New Zealand	0.55
Ukraine	0.50
Puerto Rico	0.48
Bulgaria	0.47
Lithuania	0.46
Serbia	0.45
Oman	0.44
Poland	0.43
Estonia	0.42

Enrollment Rate Landscape



Results



Reduction in time spent identifying suitable trial sites and investigators



Increased confidence in site selection with benchmarked performance metrics



Enhanced protocol feasibility with insights into screen failure and retention rates



Faster decision-making with AI-powered research assistance



More efficient study start-up through streamlined analytics and automation



Unbiased site selection through proprietary **Site Compare Tool**

Conclusion

Trialtrove+ and Sitetrove+ empower clinical teams with exclusive insights from proprietary datasets, AI-powered chat assistant, and advanced analytics, enabling faster, smarter, and more confident trial planning. With these innovations, biopharma companies can enhance site and investigator selection, optimize study feasibility, benchmark performance, and ultimately accelerate clinical trial success.

“It gives me **confidence** in bringing new countries, start-up timelines, patient counts to my leadership to get a green light on the strategy. We can build this benchmarking into our regulatory submissions: We anticipate that the trial will take X months for enrollment based on the screen failure rate, the patient per site per month. **It would give me a lot of confidence, and a different perspective from the CRO.**”

HEAD OF PATIENT RECRUITMENT AND FEASIBILITY AT MID-SIZE PHARMA

About Citeline

Citeline, a [Norstella](#) company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.

Our global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical, and medtech industries, covering them with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world's most trusted life science partners, visit [Citeline](#) and follow on [LinkedIn](#) and [X](#).